Processa Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROCESSA PHARMACEUTICALS, INC. | |
| By: | /s/ George Ng |
| George Ng | |
| Chief Executive Officer (Principal Executive Officer) | |
| Dated: | March 18, 2026 |
| By: | /s/ Russell Skibsted |
| Russell Skibsted | |
| Chief Financial Officer (Principal Financial and Accounting Officer) | |
| Dated: | March 18, 2026 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Capacity | Date |
|---|---|---|
| /s/ George Ng | Chief Executive Officer | March 18, 2026 |
| George Ng | ||
| /s/ Russell Skibsted | Chief Financial Officer | March 18, 2026 |
| Russell Skibsted | ||
| /s/ David Young | President of Research and Development and Director | March 18, 2026 |
| David Young | ||
| /s/ Khoso Baluch | Director | March 18, 2026 |
| Khoso Baluch | ||
| /s/ James Neal | Director | March 18, 2026 |
| James Neal | ||
| /s/ Geraldine Pannu | Director | March 18, 2026 |
| Geraldine Pannu | ||
| /s/ Justin Yorke | Director | March 18, 2026 |
| Justin Yorke | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.